Journal of the Korean Society of Radiology (대한영상의학회지)

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

LI-RADS Treatment Response versus Modified RECIST for Diagnosing Viable Hepatocellular Carcinoma after Locoregional Therapy: A Systematic Review and Meta-Analysis of Comparative Studies

국소 치료 후 잔존 간세포암의 진단을 위한 LI-RADS 치료 반응 알고리즘과 Modified RECIST 기준 간 비교: 비교 연구를 대상으로 한 체계적 문헌고찰과 메타분석

  • Dong Hwan Kim (Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Bohyun Kim (Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Joon-Il Choi (Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Soon Nam Oh (Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Sung Eun Rha (Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • 김동환 (가톨릭대학교 의과대학 서울성모병원 영상의학과) ;
  • 김보현 (가톨릭대학교 의과대학 서울성모병원 영상의학과) ;
  • 최준일 (가톨릭대학교 의과대학 서울성모병원 영상의학과) ;
  • 오순남 (가톨릭대학교 의과대학 서울성모병원 영상의학과) ;
  • 나성은 (가톨릭대학교 의과대학 서울성모병원 영상의학과)
  • Received : 2021.11.01
  • Accepted : 2022.01.12
  • Published : 2022.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose To systematically compare the performance of liver imaging reporting and data system treatment response (LR-TR) with the modified Response Evaluation Criteria in Solid Tumors (mRECIST) for diagnosing viable hepatocellular carcinoma (HCC) treated with locoregional therapy (LRT). Materials and Methods Original studies of intra-individual comparisons between the diagnostic performance of LR-TR and mRECIST using dynamic contrast-enhanced CT or MRI were searched in MEDLINE and EMBASE, up to August 25, 2021. The reference standard for tumor viability was surgical pathology. The meta-analytic pooled sensitivity and specificity of the viable category using each criterion were calculated using a bivariate random-effects model and compared using bivariate meta-regression. Results For five eligible studies (430 patients with 631 treated observations), the pooled per-lesion sensitivities and specificities were 58% (95% confidence interval [CI], 45%-70%) and 93% (95% CI, 88%-96%) for the LR-TR viable category and 56% (95% CI, 42%-69%) and 86% (95% CI, 72%-94%) for the mRECIST viable category, respectively. The LR-TR viable category provided significantly higher pooled specificity (p < 0.01) than the mRECIST but comparable pooled sensitivity (p = 0.53). Conclusion The LR-TR algorithm demonstrated better specificity than mRECIST, without a significant difference in sensitivity for the diagnosis of pathologically viable HCC after LRT.

목적 국소 치료 후 잔존 간세포암 진단을 위한 LI-RADS 치료 반응(liver imaging reporting and data system treatment response; 이하 LR-TR)과 modified Response Evaluation Criteria in Solid Tumors (이하 mRECIST) 기준의 진단능을 체계적으로 비교한다. 대상과 방법 MEDLINE과 EMBASE에서 역동적 조영증강 CT 또는 MRI를 이용하여 LR-TR과 mRECIST의 진단능을 개인 내 비교한 원저를 검색하였다. 생존 종양에 대한 참조 표준은 수술을 통한 병리 진단을 사용하였다. 각 기준의 생존 카테고리에 대한 메타분석적 통합 민감도와 특이도는 bivariate random-effects model을 통해 계산하였고 bivariate meta-regression을 통해 비교하였다. 결과 총 다섯 개의 포함된 연구들에서(430명 환자들 및 631개 치료된 병변들), LR-TR 생존 카테고리의 병변별 통합 민감도와 특이도는 58% (95% 신뢰구간, 45%-70%)와 93% (95% 신뢰구간, 88%-96%)이었으며 mRECIST 생존 카테고리는 56% (95% 신뢰구간, 42%-69%)와 86% (95% 신뢰구간, 72%-94%)이었다. LR-TR 생존 카테고리는 mRECIST에 비하여 유의하게 높은 특이도를 보였으나(p < 0.01) 민감도는 유사하였다(p = 0.53). 결론 LR-TR 알고리즘은 국소 치료 후 병리학적 잔존 간세포암의 진단에 대하여 민감도의 유의한 차이 없이 mRECIST보다 높은 특이도를 보였다.

Keywords

References

  1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182-236
  2. Ho MH, Yu CY, Chung KP, Chen TW, Chu HC, Lin CK, et al. Locoregional therapy-induced tumor necrosis as a predictor of recurrence after liver transplant in patients with hepatocellular carcinoma. Ann Surg Oncol 2011;18:3632-3639
  3. Allard MA, Sebagh M, Ruiz A, Guettier C, Paule B, Vibert E, et al. Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation? J Hepatol 2015;63:83-92
  4. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358-380
  5. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60
  6. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001;35:421-430
  7. Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, et al. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J Hepatol 2017;66:1166-1172
  8. American College of Radiology. CT/MRI LI-RADS® v2017. Available at. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2017. Published 2017. Accessed Oct 5, 2021
  9. Seo N, Kim MS, Park MS, Choi JY, Do RKG, Han K, et al. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with liver imaging reporting and data system version 2017. Eur Radiol 2020;30:261-271
  10. Bae JS, Lee JM, Yoon JH, Kang HJ, Jeon SK, Joo I, et al. Evaluation of LI-RADS version 2018 treatment response algorithm for hepatocellular carcinoma in liver transplant candidates: intraindividual comparison between CT and hepatobiliary agent-enhanced MRI. Radiology 2021;299:336-345
  11. Kierans AS, Najjar M, Dutruel SP, Gavlin A, Chen C, Lee MJ, et al. Evaluation of the LI-RADS treatment response algorithm in hepatocellular carcinoma after trans-arterial chemoembolization. Clin Imaging 2021;80:117-122
  12. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700
  13. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-536
  14. Deville WL, Buntinx F, Bouter LM, Montori VM, de Vet HC, van der Windt DA, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2002;2:9
  15. King MJ, Tong A, Dane B, Huang C, Zhan C, Shanbhogue K. Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes. Eur J Radiol 2020;133:109351
  16. Youn SY, Kim DH, Choi JI, Choi MH, Kim B, Shin YR, et al. Usefulness of arterial subtraction in applying liver imaging reporting and data system (LI-RADS) treatment response algorithm to gadoxetic acid-enhanced MRI. Korean J Radiol 2021;22:1289-1299
  17. Youn SY, Kim DH, Choi SH, Kim B, Choi JI, Shin YR, et al. Diagnostic performance of liver imaging reporting and data system treatment response algorithm: a systematic review and meta-analysis. Eur Radiol 2021;31:4785-4793
  18. Kim TH, Woo S, Joo I, Bashir MR, Park MS, Burke LMB, et al. LI-RADS treatment response algorithm for detecting incomplete necrosis in hepatocellular carcinoma after locoregional treatment: a systematic review and meta-analysis using individual patient data. Abdom Radiol (NY) 2021;46:3717-3728
  19. Huh YJ, Kim DH, Kim B, Choi JI, Rha SE. Per-feature accuracy of liver imaging reporting and data system locoregional treatment response algorithm: a systematic review and meta-analysis. Cancers (Basel) 2021;13:4432
  20. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-442
  21. Ng J, Wu J. Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences. Hepat Mon 2012;12:e7635
  22. Mendiratta-Lala M, Masch WR, Shampain K, Zhang A, Jo AS, Moorman S, et al. MRI assessment of hepatocellular carcinoma after local-regional therapy: a comprehensive review. Radiol Imaging Cancer 2020;2:e190024